AbbVie Inc. (ABBV)
Pre-market:
| Previous close | 146.60 |
| Open | 145.93 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 800 |
| Day's range | 143.44 - 145.93 |
| 52-week range | 134.09 - 175.91 |
| Volume | |
| Avg. volume | 5,433,560 |
| Market cap | 256.06B |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | 49.72 |
| EPS (TTM) | 2.91 |
| Earnings date | 31 Jan 2023 - 06 Feb 2023 |
| Forward dividend & yield | 5.64 (3.67%) |
| Ex-dividend date | 13 Oct 2022 |
| 1y target est | 158.66 |
- Zacks
AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool
2 Surefire Stocks to Buy in 2023 and Hold for at Least the Next Decade
The healthcare industry has proven to be a remarkably resilient place to put capital to work in a wide range of environments. From life-saving medicines and therapies to vaccines, these are just a few examples of the essential products that healthcare companies make that render them particularly defensive investments in a bearish environment. AbbVie (NYSE: ABBV) is a pharmaceutical giant.
- Motley Fool
3 Ultra-Profitable Businesses to Invest in for the Long Haul
If its profit margins are low, then it could easily swing to a loss if it faces headwinds or the economy as a whole struggles. A higher profit margin can also create an important buffer for the business, allowing it to reduce prices if it needs to be more competitive or to better handle inflationary pressures. Three businesses that are performing exceptionally well with profit margins of 20% and higher include AbbVie (NYSE: ABBV), Nvidia (NASDAQ: NVDA), and Visa (NYSE: V).
